Why the study?
Primary splenic angiosarcoma is rare, presents a diagnostic challenge due to variegated histology, lacks standard chemotherapy, and carries a poor prognosis.
Primary splenic angiosarcoma is a rare and aggressive tumor with a poor prognosis and no standard chemotherapy treatment.
Rare splenic angiosarcoma case in young adult underscores diagnostic challenges; leaves optimal management open pending prospective data.
This paper describes a case of an aggressive primary splenic angiosarcoma in a 29-year-old man and makes a review of its clinicai findings, pathologic reports, treatment and prognosis. Angiosarcomas comprise less than 1% of soft tissue sarcomas, and only a small percentage of these tumors arise in the spleen. These tumors usually represent a diagnostic challenge for the pathologist in view of its variegated histology, and the development of new immu-nohistochemical markers for vascular tumors like CD31 (platelet-endothelial cell adhesion molecule) helps to rule out other diagnoses. There is no standard chemotherapy treatment for angiosarcomas, and the prognosis of splenic angiosarcoma is particularly poor.
No takes yet. Share an insight, caveat, or question.
Venegas et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: